AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 273: H1927-H1932, 1997;
0363-6135/97 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilcox, C. S.
Right arrow Articles by Welch, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilcox, C. S.
Right arrow Articles by Welch, W. J.
Vol. 273, Issue 4, H1927-H1932, October 1997

Role of AVP in pressor responses during activation of central TxA2/PGH2 receptors

Christopher S. Wilcox, Hubin Gao, Joseph G. Verbalis, and William J. Welch

Division of Nephrology and Hypertension and Division of Endocrinology and Metabolism, Georgetown University Medical Center, Washington, District of Columbia 20007

Administration of thromboxane A2/prostaglandin H2 (TxA2/PGH2)-receptor agonist U-46619 (2.86 nmol/kg iv) to conscious rats increased mean arterial pressure (MAP) by 17 ± 2 mmHg (n = 6; P < 0.001) and plasma arginine vasopressin (AVP) by 3.5 ± 1.1 IU/ml (n = 6; P < 0.001). Ifetroban (TxA2/PGH2 antagonist; intracerebroventricularly) prevented both responses. Intracerebroventricular U-46619 increased MAP in Long-Evans rats (n = 6) more than in AVP-deficient Brattleboro rats. AVP V1-receptor antagonist d(CH2)5Tyr(Me)AVP (3 µg/kg iv) blocked 67 ± 5% and 69 ± 7% of pressor response to intravenous AVP and intracerebroventricular U-46619, respectively. AVP (10 ng/kg iv) increased AVP by 4.7 ± 0.5 pg/ml, comparable to the increase of 3.5 ± 1.2 pg/ml with intracerebroventricular U-46619 (2.86 nmol/kg), but the rise in MAP was only one-half as great (+8 ± 3 mmHg for AVP vs. +17 ± 2 mmHg for U-46619; P < 0.05). In conclusion, U-46619 raises blood pressure and releases AVP by activating brain receptors. AVP explains approximately one-half of the pressor response.

vasopressin; thromboxane A2/prostaglandin H2 receptors; ifetroban; brain; U-46619


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. J. Welch, K. Patel, P. Modlinger, M. Mendonca, N. Kawada, K. Dennehy, S. Aslam, and C. S. Wilcox
Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2644 - H2649.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. Kitiyakara, W. J. Welch, J. G. Verbalis, and C. S. Wilcox
Role of thromboxane receptors in the dipsogenic response to central angiotensin II
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2002; 282(3): R865 - R869.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online